InterVenn welcomes Andrew Quong, PhD, as CEO!

Be part of the breakthrough

At InterVenn Biosciences, we’ve developed a platform to unlock the glycoproteome, thereby enabling novel insights into disease biology. With access to this hidden layer of biology, we have the opportunity to uncover novel solutions to previously unsolvable problems, leading to breakthrough discoveries in precision medicine.

GET BEHIND THE SHIFT FROM DISEASE MANAGEMENT TO PREVENTIVE CARE

Interested in joining our mission as an investor?

Help advance precision medicine by joining our mission as an investor

Current Investors

Get in touch